Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

May

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

Advanced CKM Syndrome Associated With Greater Cancer Risk

Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL

Adjuvant Hepatic Arterial Infusion After Surgery for Four or More Colorectal Liver Metastases

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation